Superworth

Anaptysbio free cash flow ANAB

Cash from operations less capital spending, by quarter and over the last twelve months, from 2016.

Last 12 months, to Mar 31, 2026
$4.4M
Latest quarter, Q2 FY26
−$25.9M
Fiscal year 2025
$19.6M

Anaptysbio's free cash flow was $4.4M over the twelve months to Mar 31, 2026.

In its latest quarter, Q2 FY26, it was −$25.9M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025$19.6Mn/a
FY2024−$135.7Mn/a
FY2023−$121.6Mn/a
FY2022−$74Mn/a
FY2021−$47.3Mn/a
FY2020−$14.7Mn/a
FY2019−$70.3Mn/a
FY2018−$49.6Mn/a
FY2017−$19.7Mn/a
FY2016−$9.1Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$25.9Mn/a$4.4M
Q4 FY25$98Mn/a$19.6M
Q3 FY25−$27.4Mn/a−$145.3M
Q2 FY25−$40.3Mn/a−$128.1M
Q1 FY25−$10.7Mn/a−$109.2M
Q4 FY24−$66.9Mn/a−$135.7M
Q3 FY24−$10.1Mn/a−$103.4M
Q2 FY24−$21.4Mn/a−$129.9M
Q1 FY24−$37.3Mn/a−$134.1M
Q4 FY23−$34.6Mn/a−$121.6M
Q3 FY23−$36.6Mn/a−$97.8M
Q2 FY23−$25.6Mn/a−$79M

Against its peers

Companies in Drug Manufacturers - General nearest Anaptysbio's size, closest first, today.

CompanyFree cash flow yield
ANABAnaptysbion/m
PCRXPacira BioSciences12.4%
PAHCPhibro Animal Health0.6%
ANIPANI Pharmaceuticals10.4%
OMEROmeros−5.7%
AMPHAmphastar Pharmaceuticals14.3%
HRMYHarmony Biosciencesn/m
PBHPrestige Consumer Healthcare10.4%
ABUSArbutus Biopharman/m
NRIXNurix Therapeutics13.4%
COLLCollegium Pharmaceuticaln/m
Peer median10.4%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Anaptysbio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.